# US 2025/0082330 A1 · Non-woven graft materials for nerve repair and regeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082330 A1
- Document ID: US20250082330A1
- Status: Published application
- Kind: A1
- Application number: 18/946,153
- Filed: 2024-11-13
- Published: 2025-03-13
- Earliest claimed: 2021-09-07
- Applicants: Acera Surgical, Inc.
- Inventors: Matthew R. MacEwan; Lily Jeng; Abdolrasol Rahimi; Manisha Jassal; Tamas Kovacs
- Web page: https://patentgrep.com/patent/US20250082330A1

## CPC

- A61B 17/1128: {of nerves}
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/225: {Fibrin; Fibrinogen}
- A61L 27/24: Collagen
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61L 27/58: Materials at least partially resorbable by the body
- A61L 2300/412: Tissue-regenerating or healing or proliferative agents
- A61L 2300/604: Biodegradation
- A61L 2430/32: for nerve reconstruction
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

Disclosed herein are non-woven graft materials for use in specialized surgical procedures involving nerve repair and regeneration. Some embodiments describe electrospun fiber products such as conduits, wraps, or grafts comprising a resorbable hybrid-scale matrix to facilitate nerve repair and regeneration.

## Claims

### Claim 1

(canceled)

### Claim 2

A method for facilitating nerve repair and regeneration, the method comprising:
identifying injured nerve tissue in a patient;
surgically isolating the injured nerve tissue;
inserting a hybrid-scale fiber matrix to a target site; and
securing the hybrid-scale fiber matrix to the injured nerve tissue.

### Claim 3 (depends on 2)

The method of claim 2, further comprising releasing one or more therapeutically active molecules or biological therapeutics via one or more of surface functionalization, bulk loading, physical entrapment, or progressive degradation over a defined period of time.

### Claim 4 (depends on 2)

The method of claim 2, further comprises applying a solvent comprising at least one of HFIP, DMF, DCM, Acetone, Chloroform, THF, Acetic Acid, Formic Acid, Trifluoroethanol, or Ethyl acetate.

### Claim 5 (depends on 2)

The method of claim 2, wherein the hybrid-scale fiber matrix comprises an inner fiber layer comprising uniaxially-aligned or longitudinally-aligned fibers and an outer fiber layer comprises randomly-aligned fibers, wherein the hybrid-scale fiber matrix comprises hybrid-scale fibers comprising fibers having a range of fiber diameters between 10 nm and 10,000 nm.

### Claim 6 (depends on 2)

The method of claim 2, wherein the hybrid-scale fiber matrix is secured to the injured nerve tissue using one or more techniques including suturing, tissue adhesive, or gravity.

### Claim 7 (depends on 2)

The method of claim 2, wherein the hybrid-scale fiber matrix for repairing injured nervous tissue, wherein the hybrid-scale fiber matrix is secured end-to-end or in-line with injured nerve tissue.

### Claim 8 (depends on 2)

The method of claim 2, wherein the injured nerve tissue comprises a peripheral nerve.

### Claim 9 (depends on 2)

The method of claim 2, wherein the method is used for at least one of wound repair, oral surgery, dermal repair and regeneration, head and neck surgery, endonasal surgery, and bone repair.

### Claim 10 (depends on 2)

The method of claim 2, wherein the hybrid-scale fiber matrix comprises a shape geometry selected from a group consisting of a tube, a conduit, a graft, a wrap, or a spiral wrap.

### Claim 11 (depends on 2)

The method of claim 2, wherein the hybrid-scale fiber matrix comprise hybrid-scale fibers comprising a resorbable polymer selected from a group of polymers comprising a combination of polycaprolactone, polylactic acid, polyglycolic acid, polydioxanone, PEO, PEG, and poly(3-hydroxybutyrate-co-3-hydroxyvalerate).

### Claim 12 (depends on 2)

The method of claim 2, wherein the hybrid-scale fiber matrix comprise hybrid-scale fibers that comprise biologically derived and natural materials selected from a group of materials comprising at least one of collagen, elastin, laminin, or fibrin.

### Claim 13 (depends on 2)

The method of claim 2, wherein the hybrid-scale fiber matrix comprise hybrid-scale fibers that are distributed in a bimodal distribution, wherein at least 25% of the hybrid-scale fibers possessing a diameter less than 1000 nm and at least 25% of fibers possessing a diameter greater than 1000 nm.

### Claim 14 (depends on 2)

The method of claim 2, wherein the hybrid-scale fiber matrix comprises a mean pore size less than 300 μm2.

### Claim 15 (depends on 2)

The method of claim 2, wherein the hybrid-scale fiber matrix comprise hybrid-scale fibers that are configured to progressively resorb over time in parallel with tissue regeneration and formation in a time period between 4 to 100 weeks.

### Claim 16 (depends on 5)

The method of claim 5, wherein a total thickness of the inner fiber layer and the outer fiber layer comprises at least one of a range between 250 microns and 550 microns or a range between 100 microns and 600 microns.

### Claim 17 (depends on 5)

The method of claim 5, wherein a thickness of the inner fiber layer ranges between 0 to 50% of a total thickness of both the inner fiber layer and the outer fiber layer.

### Claim 18 (depends on 2)

The method of claim 2, wherein a tensile strength of the hybrid-scale fiber matrix is at least 10.5 N, a suture pullout strength of the hybrid-scale fiber matrix is at least 1 N, and a compressive strength of the hybrid-scale fiber matrix is greater than 0.25 N.

### Claim 19 (depends on 5)

The method of claim 5, wherein the hybrid-scale fiber matrix comprises at least one of:
an inner diameter of the inner fiber layer is less than 2 microns, and an outer diameter of the outer fiber layer is between 1.5 mm and 10 mm,
a length of the hybrid-scale fiber matrix that is between 8 mm to 30 mm,
a length of the hybrid-scale fiber matrix is at least 5 mm,

### Claim 20 (depends on 2)

The method of claim 2, wherein the hybrid-scale fiber matrix comprises a volumetric density of uniaxially aligned or longitudinally-aligned fibers that is at least one of: between 0-25%, wherein a mean pore size of the hybrid-scale fiber matrix is less than 300 μm2, or between 0-50%.

### Claim 21 (depends on 5)

The method of claim 5, wherein the outer fiber layer comprises an outer lumen contacting an outer surface of the inner fiber layer, wherein an overhang defined by a difference in an end of the inner fiber layer and an end of the outer fiber layer is between 1-10 mm.
